Degarelix

[MAF] Degarelix Powder And Solvent For Solution For Injection 80 mg, 120 mg

1. Treatment of patients with advanced hormone-dependent prostate cancer.

[MSHL] Degarelix Powder And Solvent For Solution For Injection 80 mg, 120 mg

1. Treatment of patients with advanced hormone-dependent prostate cancer.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

19/12/2022 Review of cancer drugs for prostate cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

• Degarelix 80 mg and 120 mg injections;

• Enzalutamide 40 mg capsule; and

• Olaparib 100 mg and 150 mg tablets

for treating prostate cancer in line with specific clinical criteria.

Subsidy status

[R] Degarelix 80 mg and 120 mg injections are recommended for inclusion on the Medication Assistance Fund (MAF) for treating advanced hormone-dependent prostate cancer with effect from 4 January 2022.

[R] Enzalutamide 40 mg capsule, in combination with androgen deprivation therapy (ADT) is recommended for inclusion on MAF with effect from 1 September 2022 for treating:

• high-risk non-metastatic castration-resistant prostate cancer (nmCRPC);

• metastatic hormone-sensitive prostate cancer (mHSPC); and

• metastatic castration-resistant prostate cancer (mCRPC).

[R] Olaparib 100 mg and 150 mg tablets are recommended for inclusion on MAF with effect from 1 September 2022, for treating patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) whose disease has progressed following prior treatment with abiraterone or a second-generation anti-androgen. Androgen deprivation therapy (ADT) should be continued.

[NR] MAF assistance does not apply to apalutamide 60 mg tablet, darolutamide 300 mg tablet, olaparib 50 mg capsule or cabazitaxel 60 mg/1.5 mL injection for the treatment of prostate cancer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration